Spherix Global Insights Reveals Unmet Need Driving Interest in Emerging Therapies for Thyroid Eye Disease
Physicians highlight early intervention, safety, and access limitations as key unmet needs—Tepezza SC anticipated to reshape the treatment paradigm in 2026 EXTON, PA, November 12, 2025 — New research from Spherix Global Insights finds that while Amgen’s Tepezza (teprotumumab) continues to anchor the treatment landscape for thyroid eye disease (TED), physicians emphasize ongoing unmet needs—particularly […]
